ENTITY

Nanjing Novlead Biotechnology (NVLD HK)

2
Analysis
Health Care • Hong Kong
Nanjing Novlead Biotechnology, incorporated in 2018, operates in the gas-based cardiopulmonary device market, focusing on inhaled nitric oxide (iNO) therapy. The company is seeking to list on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules, with its Core Product, iNOwill, approved by the NMPA in 2022 and EU CE certified in 2025.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x